Cargando…
Effects of oral isotretinoin therapy on the nasal cavities()()
INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422455/ https://www.ncbi.nlm.nih.gov/pubmed/30472003 http://dx.doi.org/10.1016/j.bjorl.2018.10.004 |
_version_ | 1784777815972904960 |
---|---|
author | Tasli, Hamdi Yurekli, Aslan Gokgoz, Mert Cemal Karakoc, Omer |
author_facet | Tasli, Hamdi Yurekli, Aslan Gokgoz, Mert Cemal Karakoc, Omer |
author_sort | Tasli, Hamdi |
collection | PubMed |
description | INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints of patients with severe acne who received oral isotretinoin therapy. METHODS: Fifty-four subjects were enrolled in the study. All the subjects were assessed with subjective (NOSE and VAS questionnaires) and objective (rhinomanometry and saccharine) tests to determine the severity of their nasal complaints. RESULTS: The mean severity scores (min: 0; max: 100) for nasal dryness/crusting and epistaxis were 0.47 ± 1.48 (0–5); 0.35 ± 1.30 (0–5) at admission, 3.57 ± 4.45 (0–10); 2.26 ± 4.71 (0–20) at the first month, and 4.28 ± 6 (0–20); 2.26 ± 4.71 (0–20) at the third month of the treatment respectively. Total nasal resistance of 0.195 ± 0.079 (0.12–0.56) Pa/cm(3)/s at admission, 0.21 ± 0.084 (0.12–0.54) Pa/cm(3)/s at the first month, and 0.216 ± 0.081 (0.14–0.54) Pa/cm(3)/s at the third month. CONCLUSION: Oral isotretinoin therapy can cause the complaint of nasal obstruction. In addition, nasal complaints, such as dryness/crusting and epistaxis, significantly increase in patients during the therapy schedule. |
format | Online Article Text |
id | pubmed-9422455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94224552022-08-31 Effects of oral isotretinoin therapy on the nasal cavities()() Tasli, Hamdi Yurekli, Aslan Gokgoz, Mert Cemal Karakoc, Omer Braz J Otorhinolaryngol Original Article INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints of patients with severe acne who received oral isotretinoin therapy. METHODS: Fifty-four subjects were enrolled in the study. All the subjects were assessed with subjective (NOSE and VAS questionnaires) and objective (rhinomanometry and saccharine) tests to determine the severity of their nasal complaints. RESULTS: The mean severity scores (min: 0; max: 100) for nasal dryness/crusting and epistaxis were 0.47 ± 1.48 (0–5); 0.35 ± 1.30 (0–5) at admission, 3.57 ± 4.45 (0–10); 2.26 ± 4.71 (0–20) at the first month, and 4.28 ± 6 (0–20); 2.26 ± 4.71 (0–20) at the third month of the treatment respectively. Total nasal resistance of 0.195 ± 0.079 (0.12–0.56) Pa/cm(3)/s at admission, 0.21 ± 0.084 (0.12–0.54) Pa/cm(3)/s at the first month, and 0.216 ± 0.081 (0.14–0.54) Pa/cm(3)/s at the third month. CONCLUSION: Oral isotretinoin therapy can cause the complaint of nasal obstruction. In addition, nasal complaints, such as dryness/crusting and epistaxis, significantly increase in patients during the therapy schedule. Elsevier 2018-11-12 /pmc/articles/PMC9422455/ /pubmed/30472003 http://dx.doi.org/10.1016/j.bjorl.2018.10.004 Text en © 2018 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Tasli, Hamdi Yurekli, Aslan Gokgoz, Mert Cemal Karakoc, Omer Effects of oral isotretinoin therapy on the nasal cavities()() |
title | Effects of oral isotretinoin therapy on the nasal cavities()() |
title_full | Effects of oral isotretinoin therapy on the nasal cavities()() |
title_fullStr | Effects of oral isotretinoin therapy on the nasal cavities()() |
title_full_unstemmed | Effects of oral isotretinoin therapy on the nasal cavities()() |
title_short | Effects of oral isotretinoin therapy on the nasal cavities()() |
title_sort | effects of oral isotretinoin therapy on the nasal cavities()() |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422455/ https://www.ncbi.nlm.nih.gov/pubmed/30472003 http://dx.doi.org/10.1016/j.bjorl.2018.10.004 |
work_keys_str_mv | AT taslihamdi effectsoforalisotretinointherapyonthenasalcavities AT yurekliaslan effectsoforalisotretinointherapyonthenasalcavities AT gokgozmertcemal effectsoforalisotretinointherapyonthenasalcavities AT karakocomer effectsoforalisotretinointherapyonthenasalcavities |